Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

EMA validates X4 Pharma’s marketing authorization application for mavorixafor to treat WHIM syndrome: Boston Monday, January 27, 2025, 11:00 Hrs [IST] X4 Pharmaceuticals, a comp ...

X4 Pharmaceuticals, Inc.’s XFOR share price has surged by 52.59%, which has investors questioning if this is right time to ...

Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for ...

KUDO, the world's leading provider of language accessibility technology, has announced the release of its revamped mobile app for real-time, on-demand conversational speech translation. Available on ...

for the treatment of patients with agammaglobulinemia or hypogammaglobulinemia. These conditions, characterized by low or absent antibody levels, result in an increased risk of serious infections.

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

The adaptive immune system is an antigen-specific structure that discriminates non-self molecules through the recognition of peptide antigens using receptor interactions between T-cells and ...

In contrast to acquired rubella infection, congenital infection results in persistent progressive infection. Contact isolation is required for neonates suspected to have congenital rubella.

After hours: January 28 at 5:55:39 p.m. EST ...

Brian Feth, Jonathan Grinstein, PhD, Beth Willers, and Laks Pernenkil go behind the headlines to discuss major news announcements made during the JP Morgan Healthcare Conference, a wave of new ...